Antidiabetic Glucagon Like Peptide 1 Agonists Market: Future Outlook and Trends 2035 www.wiseguyreports.com/reports/anti...
Antidiabetic Glucagon Like Peptide 1 Agonists Market: Future Outlook and Trends 2035
Antidiabetic Glucagon Like Peptide 1 Agonists Market Size was estimated at 18.2 (USD Billion) in 2023. The Antidiabetic Glucagon Like Peptide 1 Agonists Market Industry is expected to grow from 20.15(...
www.wiseguyreports.com
February 14, 2026 at 10:53 AM
Antidiabetic Glucagon Like Peptide 1 Agonists Market: Future Outlook and Trends 2035 www.wiseguyreports.com/reports/anti...
Also survodutide phase 3 data will be presented there as well. It's a dual GLP1/Glucagon agonist. Actually big number of presentations will revolve around the role of glucagon agonism and it's benefits
February 13, 2026 at 11:35 PM
Also survodutide phase 3 data will be presented there as well. It's a dual GLP1/Glucagon agonist. Actually big number of presentations will revolve around the role of glucagon agonism and it's benefits
Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Atherosclerotic Cardiovascular Risk Among Patients With Type 2 Diabetes in Primary Health Care Settings in Jeddah, Saudi Arabia
https://www.newsbeep.com/nz/281662/
Specialty …
https://www.newsbeep.com/nz/281662/
Specialty …
Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Atherosclerotic Cardiovascular Risk Among Patients With Type 2 Diabetes in Primary Health Care Settings in Jeddah, Saudi Arabia - New Zealand News Beep
Specialty
www.newsbeep.com
February 13, 2026 at 5:30 AM
Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Atherosclerotic Cardiovascular Risk Among Patients With Type 2 Diabetes in Primary Health Care Settings in Jeddah, Saudi Arabia
https://www.newsbeep.com/nz/281662/
Specialty …
https://www.newsbeep.com/nz/281662/
Specialty …
Ophthopedia Update: Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor… #Ophthalmology #Ophthotwitter #Scicomm
Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown superior efficacy in glycemic control, weight loss, and cardiometabolic outcomes compared to GLP-1 RAs alone. While GLP-1 RAs may offer neuroprotective effects relevant to glaucoma, the impact of dual-incretin therapies like tirzepatide on glaucoma remains unknown. This study investigates the association between tirzepatide initiation and the risk of primary open-angle glaucoma (POAG), ocular hypertension (OHTN), and glaucoma treatment initiation in patients with type 2 diabetes mellitus (T2DM), compared to those initiating selective GLP-1 RAs.
dlvr.it
February 13, 2026 at 2:19 AM
Ophthopedia Update: Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor… #Ophthalmology #Ophthotwitter #Scicomm
Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials
@taneuroldisord.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#GLP-1 #neurology #openaccess
@taneuroldisord.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#GLP-1 #neurology #openaccess
February 12, 2026 at 9:34 PM
Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials
@taneuroldisord.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#GLP-1 #neurology #openaccess
@taneuroldisord.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#GLP-1 #neurology #openaccess
In laymen's terms Glucagon agonism(in rodents! Maybe humans!) is pressing all available levers to reduce body weight/find ways to preserve function in the body by burning fuel.
When you frame glucagon as both a regulatory hormone AND our starvation hormone this makes even more sense IMHO.
When you frame glucagon as both a regulatory hormone AND our starvation hormone this makes even more sense IMHO.
February 12, 2026 at 1:05 PM
In laymen's terms Glucagon agonism(in rodents! Maybe humans!) is pressing all available levers to reduce body weight/find ways to preserve function in the body by burning fuel.
When you frame glucagon as both a regulatory hormone AND our starvation hormone this makes even more sense IMHO.
When you frame glucagon as both a regulatory hormone AND our starvation hormone this makes even more sense IMHO.
Fascinating preclinical work on my favorite topic, glucagon.
This study suggests glucagon is doing a lot more than just futile cycling glucose substrates and inducing ketogenesis & lipolysis for weight loss.
This study suggests glucagon is doing a lot more than just futile cycling glucose substrates and inducing ketogenesis & lipolysis for weight loss.
GCGR agonism requires GABAergic signaling in the Medial Basal Hypothalamus to Promote Weight Loss in Obese Mice - PubMed
Glucagon receptor (GCGR)-mediated thermogenesis is a key component for the next-generation of obesity therapeutics. Herein, we investigated the central and peripheral mechanism by which activation of the GCGR augments metabolic rate to promote weight loss. Chronic treatment of obese mice with a long …
pubmed.ncbi.nlm.nih.gov
February 12, 2026 at 1:05 PM
Fascinating preclinical work on my favorite topic, glucagon.
This study suggests glucagon is doing a lot more than just futile cycling glucose substrates and inducing ketogenesis & lipolysis for weight loss.
This study suggests glucagon is doing a lot more than just futile cycling glucose substrates and inducing ketogenesis & lipolysis for weight loss.
🆕 Review article: "Proglucagon-derived peptides: human physiology and therapeutic potential."
Lærke S. Gasbjerg et al.
https://ow.ly/eHxj50YbNTZ
#Proglucagon-derivedPeptides #Coagonists #Glucagon
Lærke S. Gasbjerg et al.
https://ow.ly/eHxj50YbNTZ
#Proglucagon-derivedPeptides #Coagonists #Glucagon
February 12, 2026 at 1:00 PM
🆕 Review article: "Proglucagon-derived peptides: human physiology and therapeutic potential."
Lærke S. Gasbjerg et al.
https://ow.ly/eHxj50YbNTZ
#Proglucagon-derivedPeptides #Coagonists #Glucagon
Lærke S. Gasbjerg et al.
https://ow.ly/eHxj50YbNTZ
#Proglucagon-derivedPeptides #Coagonists #Glucagon
Bc all Dietary protein is proteins but not all proteins are dietary protein.) so like, GLP-1 is a signaling hormone that tells the pancreas to secrete insulin (it literally stands for glucagon-like-Peptide-1) but capsaicin, which makes peppers spicy is also a type of peptide.
February 12, 2026 at 1:27 AM
Bc all Dietary protein is proteins but not all proteins are dietary protein.) so like, GLP-1 is a signaling hormone that tells the pancreas to secrete insulin (it literally stands for glucagon-like-Peptide-1) but capsaicin, which makes peppers spicy is also a type of peptide.
ข้อห้ามสำคัญ * ห้ามใช้ ARBs 2 ชนิด พร้อมกัน -> เสี่ยงไตพัง + โพแทสเซียมสูง ⚠️ ยาเสริมที่ช่วยได้ (แต่ไม่ใช่เพื่อความดันล้วนๆ) * SGLT2i (เช่น Dapagliflozin, Empagliflozin, หรือ Glucagon like peptide-1) / GLP1-RA (เช่น Semaglutide, Liraglutide) *
February 11, 2026 at 8:52 PM
ข้อห้ามสำคัญ * ห้ามใช้ ARBs 2 ชนิด พร้อมกัน -> เสี่ยงไตพัง + โพแทสเซียมสูง ⚠️ ยาเสริมที่ช่วยได้ (แต่ไม่ใช่เพื่อความดันล้วนๆ) * SGLT2i (เช่น Dapagliflozin, Empagliflozin, หรือ Glucagon like peptide-1) / GLP1-RA (เช่น Semaglutide, Liraglutide) *
''GLP-1 medications—colloquially known as GLP-1s—mimic a naturally occurring hormone called glucagon-like peptide 1, which scientists have historically associated with digestion. In the traditional telling, after a meal, GLP-1 attaches to receptors in the pancreas, the gastrointestinal tract,[...]''
Can Ozempic Cure Addiction?
GLP-1 drugs, which have helped some people curb drug and alcohol use, may unlock a pathway to moderation.
www.newyorker.com
February 11, 2026 at 6:19 PM
''GLP-1 medications—colloquially known as GLP-1s—mimic a naturally occurring hormone called glucagon-like peptide 1, which scientists have historically associated with digestion. In the traditional telling, after a meal, GLP-1 attaches to receptors in the pancreas, the gastrointestinal tract,[...]''
Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis https://www.medrxiv.org/content/10.64898/2026.02.10.26345946v1
February 11, 2026 at 3:55 PM
Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis https://www.medrxiv.org/content/10.64898/2026.02.10.26345946v1
The United Kingdom’s regulatory body for medicine and health-care products issued a warning for patients using semaglutide – a glucagon-like peptide-1 receptor agonist (GLP-1s) sold under Ozempic, Wegovy and Rybelsus brands – for a rare risk of vision loss.
U.K. agency issues warning over Ozempic, other GLP-1 drugs for potential vision loss
The United Kingdom’s regulatory body for medicine and health-care products issued a warning for patients using semaglutide – a glucagon-like peptide-1 receptor agonist (GLP-1s) sold under Ozempic, Wegovy and Rybelsus brands – for a rare risk of vision loss.
bit.ly
February 10, 2026 at 5:01 PM
The United Kingdom’s regulatory body for medicine and health-care products issued a warning for patients using semaglutide – a glucagon-like peptide-1 receptor agonist (GLP-1s) sold under Ozempic, Wegovy and Rybelsus brands – for a rare risk of vision loss.
🔬 Scientists reveal RACK1 fine-tunes liver signals by organizing glucagon pathways in two compartments, enabling proper glucose production to control blood sugar while leaving insulin action unaffected.
🔗 https://ow.ly/SGxu50YbMGx
🏷️ #GutHealth
🔗 https://ow.ly/SGxu50YbMGx
🏷️ #GutHealth
February 10, 2026 at 4:30 PM
🔬 Scientists reveal RACK1 fine-tunes liver signals by organizing glucagon pathways in two compartments, enabling proper glucose production to control blood sugar while leaving insulin action unaffected.
🔗 https://ow.ly/SGxu50YbMGx
🏷️ #GutHealth
🔗 https://ow.ly/SGxu50YbMGx
🏷️ #GutHealth
In this blog piece #ChetanShah and #AnastaciaTew highlight that as the use of glucagon-like peptide-1 receptor agonists increases, so must our awareness of patients who have an eating disorder or who are at risk of developing one
#ukpharmacy #eatingdisorder #weightlossinjections
#ukpharmacy #eatingdisorder #weightlossinjections
The dark side of the ‘miracle jab’: why eating disorder safety cannot be an afterthought
In recent years, glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic (semaglutide; Novo Nordisk), Wegovy (semaglutide; Novo Nordisk) and Mounjaro (tirzepatide; Eli Lilly) have been…
buff.ly
February 10, 2026 at 8:30 AM
In this blog piece #ChetanShah and #AnastaciaTew highlight that as the use of glucagon-like peptide-1 receptor agonists increases, so must our awareness of patients who have an eating disorder or who are at risk of developing one
#ukpharmacy #eatingdisorder #weightlossinjections
#ukpharmacy #eatingdisorder #weightlossinjections
Glucagon Market Growth, Trends Analysis Report 2035 | MRFR www.marketresearchfuture.com/reports/gluc...
Glucagon Market Growth, Trends Analysis Report 2035 | MRFR
Glucagon Market growth is projected to reach USD 18.42 Billion by 2035, at a 6.72% CAGR, driven by industry size, share, top company analysis, segments research, trends, and forecast report 2025 to 20...
www.marketresearchfuture.com
February 10, 2026 at 6:36 AM
Glucagon Market Growth, Trends Analysis Report 2035 | MRFR www.marketresearchfuture.com/reports/gluc...
I've been predicting this would happen. I suspect they'll get banned in certain sports where weight matters, biking, rowing, etc.
Even more so when glucagon agonists come around(that requires more than 300 letters to explain)
Even more so when glucagon agonists come around(that requires more than 300 letters to explain)
Use of GLP-1 Drugs Under Scrutiny at Winter Olympics
Anti-doping group includes novel diabetes, weight-loss drugs in its monitoring program
www.medpagetoday.com
February 9, 2026 at 3:49 PM
I've been predicting this would happen. I suspect they'll get banned in certain sports where weight matters, biking, rowing, etc.
Even more so when glucagon agonists come around(that requires more than 300 letters to explain)
Even more so when glucagon agonists come around(that requires more than 300 letters to explain)
因為利潤太高了，假藥可能會跟當年的廣泛存在的假酒問題一樣嚴重。
FDA 擬對未經 FDA 核准的 GLP-1 藥物採取執法行動 https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
美國食品藥物管理局 FDA（Food and Drug Administration）發布聲明，表態將採取強力措施，限制用於「非 FDA 核准」的 GLP-1（glucagon-like peptide-1 receptor […]
FDA 擬對未經 FDA 核准的 GLP-1 藥物採取執法行動 https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
美國食品藥物管理局 FDA（Food and Drug Administration）發布聲明，表態將採取強力措施，限制用於「非 FDA 核准」的 GLP-1（glucagon-like peptide-1 receptor […]
Original post on mistyreverie.org
mistyreverie.org
February 9, 2026 at 6:41 AM
因為利潤太高了，假藥可能會跟當年的廣泛存在的假酒問題一樣嚴重。
FDA 擬對未經 FDA 核准的 GLP-1 藥物採取執法行動 https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
美國食品藥物管理局 FDA（Food and Drug Administration）發布聲明，表態將採取強力措施，限制用於「非 FDA 核准」的 GLP-1（glucagon-like peptide-1 receptor […]
FDA 擬對未經 FDA 核准的 GLP-1 藥物採取執法行動 https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
美國食品藥物管理局 FDA（Food and Drug Administration）發布聲明，表態將採取強力措施，限制用於「非 FDA 核准」的 GLP-1（glucagon-like peptide-1 receptor […]
📰 FDA Cracks Down on Unapproved GLP-1 Drugs
The U.S. Food and Drug Administration (FDA) has announced its intention to take enforcement actions against unapproved Glucagon-like peptide-1 (GLP-1) receptor agonist drugs. This move aims to protect public health by ensuring ...
#AINews #AI #Teknoloji
The U.S. Food and Drug Administration (FDA) has announced its intention to take enforcement actions against unapproved Glucagon-like peptide-1 (GLP-1) receptor agonist drugs. This move aims to protect public health by ensuring ...
#AINews #AI #Teknoloji
FDA Cracks Down on Unapproved GLP-1 Drugs
The U.S. Food and Drug Administration (FDA) has announced its intention to take enforcement actions against unapproved Glucagon-like peptide-1 (GLP-1) receptor agonist drugs. This move aims to protect public health by ensuring that medications used for weight loss and diabetes management meet rigoro
aihaberleri.org
February 8, 2026 at 8:34 AM
📰 FDA Cracks Down on Unapproved GLP-1 Drugs
The U.S. Food and Drug Administration (FDA) has announced its intention to take enforcement actions against unapproved Glucagon-like peptide-1 (GLP-1) receptor agonist drugs. This move aims to protect public health by ensuring ...
#AINews #AI #Teknoloji
The U.S. Food and Drug Administration (FDA) has announced its intention to take enforcement actions against unapproved Glucagon-like peptide-1 (GLP-1) receptor agonist drugs. This move aims to protect public health by ensuring ...
#AINews #AI #Teknoloji
what i would like
1. faster insulin absorption and action
2. a pump with something like glucagon to react to lows
3. smoother insurance and healthcare management that doesn't require me to keep on top of them constantly
1. faster insulin absorption and action
2. a pump with something like glucagon to react to lows
3. smoother insurance and healthcare management that doesn't require me to keep on top of them constantly
February 7, 2026 at 10:57 PM
what i would like
1. faster insulin absorption and action
2. a pump with something like glucagon to react to lows
3. smoother insurance and healthcare management that doesn't require me to keep on top of them constantly
1. faster insulin absorption and action
2. a pump with something like glucagon to react to lows
3. smoother insurance and healthcare management that doesn't require me to keep on top of them constantly
Everything you need to know about GLP-1s for weight loss
https://www.europesays.com/uk/748423/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …#uk #news #uknews
https://www.europesays.com/uk/748423/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …#uk #news #uknews
Everything you need to know about GLP-1s for weight loss - United Kingdom
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since.
www.europesays.com
February 7, 2026 at 12:40 PM
Everything you need to know about GLP-1s for weight loss
https://www.europesays.com/uk/748423/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …#uk #news #uknews
https://www.europesays.com/uk/748423/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …#uk #news #uknews
Everything you need to know about GLP-1s for weight loss
https://www.europesays.com/uk/748423/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
https://www.europesays.com/uk/748423/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
Everything you need to know about GLP-1s for weight loss - United Kingdom
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since.
www.europesays.com
February 7, 2026 at 12:40 PM
Everything you need to know about GLP-1s for weight loss
https://www.europesays.com/uk/748423/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
https://www.europesays.com/uk/748423/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
Everything you need to know about GLP-1s for weight loss
https://www.newsbeep.com/us/454077/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
https://www.newsbeep.com/us/454077/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
Everything you need to know about GLP-1s for weight loss - United States News Beep
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since.
www.newsbeep.com
February 7, 2026 at 8:00 AM
Everything you need to know about GLP-1s for weight loss
https://www.newsbeep.com/us/454077/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
https://www.newsbeep.com/us/454077/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
Everything you need to know about GLP-1s for weight loss
https://www.newsbeep.com/ca/459249/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
https://www.newsbeep.com/ca/459249/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
Everything you need to know about GLP-1s for weight loss - Canada News Beep
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since.
www.newsbeep.com
February 7, 2026 at 7:20 AM
Everything you need to know about GLP-1s for weight loss
https://www.newsbeep.com/ca/459249/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
https://www.newsbeep.com/ca/459249/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
Everything you need to know about GLP-1s for weight loss
https://www.newsbeep.com/au/463830/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
https://www.newsbeep.com/au/463830/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
Everything you need to know about GLP-1s for weight loss - Australia News Beep
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since.
www.newsbeep.com
February 7, 2026 at 6:20 AM
Everything you need to know about GLP-1s for weight loss
https://www.newsbeep.com/au/463830/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …
https://www.newsbeep.com/au/463830/
Glucagon-like peptide-1 (GLP-1) receptor agonists were touted as “breakthrough” drugs in 2023 — and their popularity has soared since. …